Q-omics provides the consensus-scored MGAT4D profile across patient tissues and cancer cell-line models. MGAT4D expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, MGAT4D is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, MGAT4D RNA expression shows 6,600 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, LUSC, and STAD as cancer lineages where MGAT4D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGAT4D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGAT4D survival associations across molecular data types. MGAT4D RNA expression shows survival associations in the most cancer types (14), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGAT4D RNA expression–survival associations across cancer types. High MGAT4D expression shows unfavorable associations in LIHC, DLBC, THCA and OV, but favorable associations in SKCM and BLCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .013). Together, the overview and detailed table identify LIHC as the clearest survival context for MGAT4D RNA expression.
This table summarizes MGAT4D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MGAT4D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGAT4D shows lower tumor expression in LUSC, LUAD, THCA and KICH and higher tumor expression in BRCA and PRAD. The LUSC box plot shows higher MGAT4D RNA expression in normal versus tumor tissue (log2 FC = −0.046, t-test p < 0.001).
This table shows molecular features associated with MGAT4D in patient tissues and cancer cell lines. In patient samples, MGAT4D shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MGAT4D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
